Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.77 |
| ▸ | DRD2 | P14416 | 2/20 | 0.74 |
| ▸ | DRD3 | P35462 | 1/20 | 0.74 |
| ▸ | MEN1 | O00255 | 2/20 | 0.68 |
| ▸ | HTR7 | P34969 | 2/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.68 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.68 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.67 |
| ▸ | ADRA1D | P25100 | 2/20 | 0.67 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.67 |
| ▸ | ADRA1B | P35368 | 2/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.67 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.67 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.67 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | GLA | P06280 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30080718 | 1.00 | HTR1A (0.77) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL30080722 | 1.00 | HTR1A (0.77) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL9527924 | 0.99 | HTR1A (0.75) | HTR1ADRD2DRD3MEN1HTR7 | |
| Hydrochloric Acid SCHEMBL3196123 | 0.99 | HTR1A (0.75) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL29395171 | 0.96 | DRD2 (0.76) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL2215388 | 0.96 | DRD2 (0.76) | HTR1ADRD2DRD3MEN1HTR7 | |
| Hydrochloric Acid SCHEMBL29072812 | 0.94 | DRD2 (0.74) | HTR1ADRD2DRD3MEN1HTR7 | |
| Hydrochloric Acid SCHEMBL11047866 | 0.94 | DRD2 (0.74) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL4404160 | 0.90 | DRD2 (0.75) | HTR1ADRD2DRD3MEN1HTR7 | |
| SCHEMBL6526368 | 0.90 | DRD2 (0.85) | HTR1ADRD2DRD3MEN1HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108329282-B | Phenylpiperazine derivative and preparation method and application thereof | 新乡医学院 | 2022-01-07 | — | — | CN | claimed |
| US-20140273458-A1 | Chemical Mechanical Planarization for Tungsten-Containing Substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-18 | — | — | US | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2010-02-04 | — | — | US | claimed |
| EP-2057138-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | Pierre Fabre Medicament (FR) | 2009-05-13 | — | — | EP | claimed |
| WO-2008009741-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | PIERRE FABRE MEDICAMENT (FR) | 2008-01-24 | — | — | WO | claimed |
| CN-117263843-A | Dopamine D 2 Receptor-like dual ligand compounds and uses thereof | 常州大学 | 2023-12-22 | — | — | CN | disclosed |
| CN-116712435-A | Application of dopamine D3 receptor ligand derivative in preparation of antidepressant drugs | 新乡医学院 | 2023-09-08 | — | — | CN | disclosed |
| CN-109419802-B | Compounds having dopamine D3 receptor modulating activity and uses thereof | 中国人民解放军军事医学科学院毒物药物研究所（CN） | 2023-01-13 | — | — | CN | disclosed |
| CN-108329282-B | Phenylpiperazine derivative and preparation method and application thereof | 新乡医学院 | 2022-01-07 | — | — | CN | disclosed |
| CN-111253325-A | Amino quinazoline aryl piperazine compound and pharmaceutical composition and application thereof | 广州大学 | 2020-06-09 | — | — | CN | disclosed |
| CN-109419802-A | Active compound and application thereof is adjusted with dopamine D 3 receptor | 中国人民解放军军事医学科学院毒物药物研究所 | 2019-03-05 | — | — | CN | disclosed |
| US-9828352-B2 | Phenyl carbamates and their use as inhibitors of the fatty acid amide hydrolase (FAAH) enzyme and modulators of the D3 dopamine receptor (D3DR) | FONDAZIONE ISTITUTO ITALIANO DI TECNOLOGIA (IT) | 2017-11-28 | — | — | US | disclosed |
| EP-0496692-A1 | 2-Methoxyphenylpiperazine derivatives | FABRICA ESPANOLA DE PRODUCTOS QUIMICOS Y FARMACEUTICOS, S.A. (FAES) (ES) | 1992-07-29 | — | — | EP | disclosed |
| US-5034391-A | Piperazinylalkyl-3(2H)-pyridazinones and the use thereof as agents lowering blood pressure | CL PHARMA AKTIENGESELLSCHAFT (AT) | 1991-07-23 | — | — | US | disclosed |
| EP-0372305-A1 | Piperazinylalkyl-3(2H)-pyridazinones, method for their preparation and their use as antihypertensive agents | Hafslund Nycomed Pharma Aktiengesellschaft (AT) | 1990-06-13 | — | — | EP | disclosed |
| US-4748240-A | Psychotropic bicyclic imides | AMERICAN HOME PRODUCTS CORPORATION (US) | 1988-05-31 | — | — | US | disclosed |
| US-4585773-A | DIURETIC, HYPOTENSIVE | BRISTOL-MYERS COMPANY (US) | 1986-04-29 | — | — | US | disclosed |
| WO-1984004302-A1 | SUBSTITUTED PICOLINIC ACIDS, PROCESSES FOR THEIR PREPARATION, THEIR USE AND MEDICAMENTS CONTAINING THEM | BYK GULDEN LOMBERG CHEM FAB (DE) | 1984-11-08 | — | — | WO | disclosed |
| US-3966950-A | ALPHA-ADRENOLYTIC ACTIVITY | ROUSSEL-UCLAF (FR) | 1976-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029682-A1 | NOVEL CHROMENE AND THIOCHROMENE CARBOXAMIDE DERIVATIVES, METHODS FOR PREPARING SAME AND THERAPEUTIC APPLICATIONS OF SAME | DRD3, CHRNA3, CHRM3 | HTR1A 66/4885DRD2 13/4885DRD3 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.